KARS1 and tuberculosis: Aminoacyl-tRNA synthetases have become the focusof drug discovery programs in several disease areas.−, , ,  Compounds that target leucyl tRNA synthetase have already enteredclinical development for TB treatment. This report focuses on lysyl tRNA synthetase (LysRS), the enzymethat charges lysyl tRNA with lysine.